#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need to know that over 650 unlicensed sellers of hemp-derived cannabinoid products operate in Tennessee, meaning patients may be purchasing unregulated products without quality assurance, accurate labeling, or safety testing. This regulatory gap creates clinical risk because patients could be exposed to contaminated products, inconsistent dosing, or mislabeled cannabinoid content that affects drug interactions and treatment outcomes. Healthcare providers should ask patients about hemp cannabinoid use and counsel them on the dangers of unregulated sources while advocating for stronger oversight in their states.
Tennessee regulators identified over 650 unlicensed sellers of hemp-derived cannabinoid products (HDCPs) following implementation of new oversight requirements on January 1, revealing significant market fragmentation in a state without medical cannabis legalization. These unlicensed vendors bypass quality control, potency testing, and safety standards that licensed sellers must meet, creating substantial risk for consumers who may unknowingly purchase adulterated or mislabeled products containing variable cannabinoid concentrations or contaminants. For clinicians in Tennessee, this enforcement action underscores the importance of counseling patients about the unregulated nature of most HDCPs available outside licensed channels and the potential for adverse effects or drug interactions from untested products. The regulatory gap is particularly concerning given that patients may turn to these unvetted sources seeking relief for pain, anxiety, or other conditions that physicians cannot address through state-approved cannabis programs. Clinicians should inquire about HDCP use during patient encounters and educate patients that products from unlicensed retailers lack the quality assurances necessary to ensure safe dosing and identify potential harmful adulterants. Patients seeking cannabinoid-based therapeutics should be directed toward licensed retailers where products are subject to regulatory oversight and testing requirements.
“When we have 650 unlicensed sellers operating in a single state, we’re essentially asking patients to play Russian roulette with product quality, potency, and contamination profiles, and that’s a clinical failure on our part as a profession and as regulators to protect the people we serve.”
🏥 The proliferation of unlicensed hemp-derived cannabinoid product sellers identified by Tennessee regulators underscores a significant gap between market expansion and oversight that directly affects clinical practice. Patients increasingly self-medicate with these readily available products without physician guidance, yet clinicians often lack reliable information about product quality, potency, contaminants, or interactions with prescribed medications. The regulatory fragmentation across states creates additional complexity, as products purchased online may not comply with local standards, and the heterogeneity of unregulated formulations makes it difficult to counsel patients on consistent dosing or adverse effects. Clinicians should proactively screen patients for cannabinoid use during medication reconciliation, recognize that “hemp-derived” does not guarantee safety or efficacy, and direct patients toward state-regulated sources when available. Given the likelihood that patients will continue accessing these products regardless of medical advice, establishing collaborative conversations about their cannabinoid use and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: